Citation Information :
Kumar V, Bidhuri Y, Nesari T, Sherkhane R, Ghildiyal S. A Critical Analysis of Medohara, Lekhana, and Karshana Plants from Nighantus: A Way Forward to Combat Obesity. J Drug Res Ayurvedic Sci 2019; 4 (2):95-102.
Aim: To compile and critically analyze the Medohara, Lekhana and Karshana drugs mentioned in Nighantus with special reference to the management of obesity with promising results.
Background: Due to sedentary lifestyle and unwholesome food habits there is an ascending graph of obesity in India and worldwide. Although contemporary science has made efforts to cope up with this alarming rise but the results are not promising. Thus, the world is looking towards ancient healing science of Ayurveda to combat the situation. Ayurvedic classics and Nighantus are the wealth of herbal drugs and dosage forms. The drugs ascribed under the heading of Medohara, Lekhana and Karshana Dravyas in Ayurveda may have anti-obesity activity. The rational use of these time tested herbs may be the answer for the management of obesity. Earlier number of studies were carried out on anti-obesity drugs described in Brihat trayi. However, the data of anti-obesity drugs described in Nighantus is not available till date. Thus, the review was conducted by reviewing the popular available Nighantus i.e. Dhanvantari Nighantu (10th–13th Centuries), Sodhala Nighantu (12th century), Madanapala Nighantu (14th century), Kaiyadeva Nighantu (15th century), Bhavaprakasha Nighantu (16th century), Raj Nighantu (17th century) and Priya Nighantu (20th century).
Review results: A total of 72 drugs were found having Medohara, Lekhana and Karshaniya effect in the Nighantus database.
Conclusion: Pharmacodynamic attributes i.e. Rasa, Guna and Veerya have individual effect in obesity. Katu Vipaka is having more significant influence in producing Medohara, Lekhana and Karshana karma which is important for management of obesity.
Clinical significance: These drugs can be validated for their anti-obesity or anti-hypolipidimic activities on the basis of preclinical and clinical studies. It will also help in selection of drugs for the management of obesity.
https://www.nhp.gov.in/lifestyle-disorder_mtlas on 05.05.2019.
https://www.medicinenet.com/script/main/art.asp?articlekey=38316as on 05.05.2019.
http://www.who.int/news-room/fact-sheets/detail/obesity-and-overweightas on 05.05.2019.
Gallagher EJ, Karnieli E, LeRoith D. The metabolic syndrome: from insulin resistance to obesity and diabetes. Endocrin Metab Clin North Am 2008;37(3):559–579. DOI: 10.1016/j.ecl.2008.05.002.
Jung UJ, Choi M-S. Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and non-alcoholic fatty liver disease. Int J Mol Sci 2014;15(4):6184–6223. DOI: 10.3390/ijms15046184.
Gallagher EJ, LeRoith D. Obesity and diabetes: the increased risk of cancer and cancer – related mortality. Physiol Rev 2015;95(3):727–748. DOI: 10.1152/physrev.00030.2014.
Susruta. In Susruta Samhita, Sutra Sthana Doshadhatumalakshayavridhi Vigyaniya Adhyaya, 15/37 Dutta Shastri KA Varanasi: Chaukhamba Sanskrit Sansthana; 2015. p. 81.
Susruta. In Susruta Samhita, Sutra Sthana Vyadhi Samudeshiya Adhyaya, 24/13 Dutta Shastri KA Varanasi: Chaukhamba Sanskrit Sansthana; 2015. p. 132.